Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130962 · ClinicalTrials.gov registry record · Phase 2
ALGRX 4975 in the Treatment of Patients With Morton's Neuroma
A Phase 2 study of Neuroma, sponsored by AlgoRx Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00130962 is a Phase 2 study of Neuroma that has completed, run by AlgoRx Pharmaceuticals. The registered enrollment target is 60 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00130962, a Phase 2 study of Neuroma, has completed, sponsored by AlgoRx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.
Conditions Studied
Interventions
- DRUG ALGRX 4975
Study Locations (2)
Maryland
- Crossroads Research, Inc. - Owings Mills
Utah
- Jean Brown Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130962
The ClinicalTrials.gov registry entry for NCT00130962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AlgoRx Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroma appearing as the primary indexed condition, and to 1 intervention - of which ALGRX 4975 is the first listed.
NCT00130962 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Utah.
Frequently Asked Questions
What is clinical trial NCT00130962 about?
NCT00130962 is a clinical study titled "ALGRX 4975 in the Treatment of Patients With Morton's Neuroma". Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects w...
What is the current status of trial NCT00130962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-09. Estimated completion is 2006-02.
What conditions does trial NCT00130962 study?
This clinical trial studies the following conditions: Neuroma.
What interventions are being tested in trial NCT00130962?
The interventions under investigation include: ALGRX 4975 (DRUG).
Who is sponsoring clinical trial NCT00130962?
This trial is sponsored by AlgoRx Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00130962 being conducted?
This trial has 2 study locations across Maryland, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.